Oral insulin therapies and protocol

• US 8,729,016 B2
• Filed: 06/16/2009
• Issued: 05/20/2014
• Est. Priority Date: 08/22/2003
• Status: Active Grant

• Current Assignee: NOVO Nordisk North America Operations A/S
• Original Assignee: Emisphere Technologies, Inc. (Novo Nordisk A/S)
• Inventors: Arbit, Ehud, Goldberg, Michael, Majuru, Shingai
• Primary Examiner(s): NOAKES, SUZANNE MARIE
• Application Number:
  US12/485,521
• Publication Number:
  US 20090253614A1
• Time in Patent Office: 1,799 Days
• Field of Search: None
• US Class Current: 514/5.9
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

Claims

1. A method for treating a human patient suffering from type 2 diabetes, resulting in a reduced risk of hyperinsulinemia to the patient, the method comprising orally administering to the patient on a chronic basis a pharmaceutical formulation comprising a therapeutically effective dose of insulin and the delivery agent 4-[(4-chloro-2-hydroxybenzoyl) amino]butanoic acid or a pharmaceutically acceptable salt thereof that facilitates absorption of insulin from the gastrointestinal tract,

wherein administration to the patient is at bedtime and preprandial all meals at from about 30 minutes prior to ingestion of a meal to concurrently with ingestion of the meal.

2. The method of claim 1, wherein said patient is at the late stage type 2 diabetes stage along said continuum of development of diabetes.

3. The method of claim 2 further comprising administering to the mammal on a chronic basis a therapeutically effective dose of a second pharmaceutical formulation comprising an intermediate-acting insulin or a long-acting insulin or both.

4. The method of claim 3 wherein the second pharmaceutical formulation is administered at least once a day orally.

5. The method of claim 3 wherein the second pharmaceutical formulation is administered at least once a day subcutaneously.

6. The method of claim 3 wherein the pharmaceutical formulation and the second pharmaceutical formulation provide two different activity rates in order to simulate the endogenous biphasic release of insulin to an ingested meal in a non-diabetic subject.

8. The method of claim 1, wherein the delivery agent is sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate.

9. The method of claim 8, wherein the delivery agent is sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate.

7. A method for treating a human patient suffering from type 2 diabetes, resulting in a reduced risk of hyperinsulinemia to the patient, the method comprising orally administering to the patient on a chronic basis of one or more pharmaceutical formulations comprising insulin and the delivery agent 4-[(4-chloro-2-hydroxybenzoyl) amino]butanoic acid, or a pharmaceutically acceptable salt thereof, that facilitates absorption of insulin from the gastrointestinal tract, wherein the total amount of 4-4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid or a pharmaceutically acceptable salt thereof and insulin at each administration is 160 mg 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid, or a pharmaceutically acceptable salt thereof, and 300 U insulin, and wherein administration to the patient is at bedtime and preprandial all meals at from about 30 minutes prior to ingestion of a meal to concurrently with ingestion of the meal.